Wall Street Zen downgraded shares of Oruka Therapeutics (NASDAQ:ORKA – Free Report) from a hold rating to a sell rating in a research report report published on Sunday.
ORKA has been the topic of a number of other reports. Piper Sandler reiterated an “overweight” rating and set a $180.00 price objective on shares of Oruka Therapeutics in a research note on Tuesday, June 2nd. HC Wainwright reiterated a “buy” rating and set a $120.00 price target on shares of Oruka Therapeutics in a research report on Monday, August 3rd. Leerink Partners set a $120.00 price objective on shares of Oruka Therapeutics in a research note on Thursday, April 30th. BTIG Research restated a “buy” rating and set a $151.00 price objective on shares of Oruka Therapeutics in a research report on Tuesday, August 11th. Finally, Guggenheim restated a “buy” rating and set a $200.00 target price on shares of Oruka Therapeutics in a research note on Tuesday, August 11th. Ten research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $134.30.
Oruka Therapeutics Stock Performance
Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04). Equities analysts forecast that Oruka Therapeutics will post -2.27 earnings per share for the current year.
Insider Activity at Oruka Therapeutics
In related news, insider Joana Goncalves sold 7,947 shares of Oruka Therapeutics stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $69.28, for a total transaction of $550,568.16. Following the sale, the insider directly owned 32,718 shares of the company’s stock, valued at approximately $2,266,703.04. The trade was a 19.54% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, SVP Arjun Agarwal sold 10,000 shares of Oruka Therapeutics stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $106.66, for a total transaction of $1,066,600.00. Following the sale, the senior vice president directly owned 15,312 shares in the company, valued at $1,633,177.92. This trade represents a 39.51% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 181,116 shares of company stock valued at $12,045,503. 23.49% of the stock is currently owned by company insiders.
Institutional Trading of Oruka Therapeutics
A number of hedge funds and other institutional investors have recently modified their holdings of ORKA. Sei Investments Co. increased its position in Oruka Therapeutics by 136.0% in the 1st quarter. Sei Investments Co. now owns 22,840 shares of the company’s stock valued at $1,120,000 after acquiring an additional 13,164 shares during the period. Moody Aldrich Partners LLC acquired a new position in Oruka Therapeutics during the 4th quarter worth about $3,844,000. Dimensional Fund Advisors LP bought a new stake in shares of Oruka Therapeutics in the 1st quarter valued at about $5,543,000. Y Intercept Hong Kong Ltd bought a new stake in shares of Oruka Therapeutics in the 1st quarter valued at about $1,811,000. Finally, The Manufacturers Life Insurance Company increased its stake in shares of Oruka Therapeutics by 18.3% in the first quarter. The Manufacturers Life Insurance Company now owns 72,563 shares of the company’s stock valued at $3,559,000 after buying an additional 11,205 shares during the period. Institutional investors own 56.44% of the company’s stock.
About Oruka Therapeutics
Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”
The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.
Read More
- Five stocks we like better than Oruka Therapeutics
- The Metals Company’s Big Bet Now Comes Down to a License
- OneSpaWorld Keeps Turning Cruise Demand Into Record Earnings
- Meta and Tesla Are Rebounding From Oversold Levels—Now What?
- AMG’s Alternatives Boom Powers Record Growth
Receive News & Ratings for Oruka Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oruka Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
